Clinical Trials

88 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06422806 2026-04-14

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

Phase 3 Recruiting

365 enrolled

Sarcoma

Liposarcoma, Histiocytoma, Malignant Fibrous

NCT01841736 2026-04-13

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

171 enrolled 15 charts

EndocrineNET

Neuroendocrine Tumors

NCT02143414 2026-04-13

Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

LymphoidOther hematologic neoplasm

53 enrolled 12 charts

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

6,452 enrolled 2 FDA

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT03017820 2026-04-13

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

127 enrolled

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT03213652 2026-04-13

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

13 enrolled

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT03233711 2026-04-13

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

Phase 3 Active not recruiting

344 enrolled

Phase 3 Active not recruiting

Anal Canal Carcinoma, Anus Neoplasms

NCT03375320 2026-04-13

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

298 enrolled 14 charts 3 FDA

EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT03831932 2026-04-13

Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

Phase 1/2 Active not recruiting

22 enrolled 12 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04090398 2026-04-13

Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones

Phase 3 Active not recruiting

70 enrolled

BreastOther neoplasm

Anatomic Stage IV Breast Cancer AJCC v8

NCT04214067 2026-04-13

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

164 enrolled

Sarcoma

Carcinosarcoma

NCT04317105 2026-04-13

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

Phase 1/2 Active not recruiting

54 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04840589 2026-04-13

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

Phase 1 Suspended

66 enrolled

Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms

NCT04847453 2026-04-13

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

24 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT05019716 2026-04-13

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

Phase 1/2 Recruiting

36 enrolled

Advanced NUT Carcinoma

NCT05075980 2026-04-13

Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study

174 enrolled

Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Lymphatic Metastasis, Mouth Neoplasms, Oropharyngeal Neoplasms, Paranasal Sinus Neoplasms, Salivary Gland Neoplasms

NCT05222620 2026-04-13

SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial

Phase 1/2 Active not recruiting

90 enrolled

CNS

Brain Neoplasms, Neoplasm Metastasis

NCT05286801 2026-04-13

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

86 enrolled

Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

NCT05372640 2026-04-13

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

45 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT05687110 2026-04-13

Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes

43 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05950464 2026-04-13

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

60 enrolled

Gynecologic

Endometrial Neoplasms

NCT06064097 2026-04-13

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

50 enrolled

Nasopharyngeal Carcinoma

NCT06136897 2026-04-13

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

35 enrolled 10 charts

Other solid neoplasm

Malignant Solid Neoplasm

NCT06169124 2026-04-13

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

37 enrolled

Granulosa cell tumor of the ovary

NCT06303167 2026-04-13

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

LymphoidOther hematologic neoplasmPlasma cell

19 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT06360588 2026-04-13

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)

22 enrolled 9 charts

Other solid neoplasm

Malignant Solid Neoplasm

NCT06454383 2026-04-13

Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

19 enrolled

Pancreatic Neoplasms

NCT06508463 2026-04-13

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

21 enrolled

Lymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT06811116 2026-04-13

Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

Phase 1/2 Recruiting

92 enrolled

Phase 2 Not yet recruiting

Carcinoma, Hepatocellular

NCT06888323 2026-04-13

Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment

Phase 1 Suspended

30 enrolled

Myeloid

Myelodysplastic Syndromes

NCT06954987 2026-04-13

Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

244 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06982222 2026-04-13

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

Phase 1 Not yet recruiting

24 enrolled

BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Prostatic Neoplasms

NCT07012044 2026-04-13

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

Phase 1 Not yet recruiting

47 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07422363 2026-04-13

Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

Phase 1 Not yet recruiting

30 enrolled

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT03699995 2026-04-08

MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma

Phase NA Terminated

17 enrolled

Dermatologic

Melanoma, Nevus, Pigmented

NCT05243069 2026-04-08

Head and Neck Cancer Patient Symptom and Oncologic Outcomes

Phase NA Completed

13 enrolled

Lymphedema of the Head and Neck

NCT07078604 2026-04-07

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

Phase 2 Not yet recruiting

20 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07511504 2026-04-06

Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma

40 enrolled

Carcinoma, Hepatocellular

NCT04333537 2026-04-03

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

Phase 2/3 Recruiting

686 enrolled